Evotec's Science Pipeline Keeps Advancing While the Share Price Sits a Hair Above Its Yearly Floor
Published on 09/12/2026 at 11:11 | Editorial boerse-global.de
Evotec's stock ended Friday at EUR 3.03, leaving the biotech services provider just 1.9% clear of its 52-week low of EUR 2.97. A 14-day relative strength index reading of 28.9 places the equity firmly in oversold territory — a technical condition that will hardly raise eyebrows among shareholders who have watched a steady stream of discouraging headlines pile up over recent weeks.
The pressure traces back to mid-July, when the company slashed its 2026 guidance. Revenue expectations were cut from a range of EUR 700 million to EUR 780 million down to EUR 570 million to EUR 610 million, while adjusted EBITDA is now projected at minus EUR 70 million to minus EUR 105 million, a stark reversal from the previously targeted break-even to plus EUR 40 million. Management attributed roughly 40% of the revenue shortfall to milestone payments slipping into 2027. When Evotec reaffirmed those reduced targets alongside its half-year report about two weeks ago, the shares responded with a further 9.9% decline.
The first-half figures themselves offered little comfort. Revenue for H1 2026 dropped 19.2% to EUR 300.1 million, and adjusted EBITDA came in at minus EUR 42.7 million. The deterioration, in other words, is not a one-quarter blip but a pattern that has been building for months.
Deals Keep Coming, but the Tape Doesn't Care
Against that grim financial backdrop, Evotec has pressed ahead with its partnership strategy — so far without any visible effect on the share price. On September 2, the company launched a research collaboration with Plectonic Biotech aimed at T-cell-engaging approaches against solid tumors, pairing its in-house BiTCo platform with Plectonic's LOGIBODY technology. Since that announcement, the stock has shed another 8.0%.
A week later, on September 9, Evotec Biologics disclosed the start of a Phase I clinical trial for JST-018, an antibody program targeting orthopoxviruses, conducted under a collaboration with the U.S. Department of War.
Should investors sell immediately? Or is it worth buying Evotec?
Further back, roughly a month ago, Evotec unveiled an AI-driven research partnership with Odyssey Therapeutics focused on autoimmune and inflammatory diseases. Financial terms were not disclosed. That news failed to halt the slide as well — the shares have lost 12.3% since.
Governance Noise Adds to the Din
Capital-markets filings have also been stacking up. Evotec published voting rights notifications relating to stake changes at JPMorgan Chase & Co. and The Goldman Sachs Group. Such disclosures are purely procedural reporting events rather than corporate news, yet they underscore the heightened market scrutiny surrounding the stock.
On the personnel front, supervisory board member Camilla Macapili Languille stepped down with effect from August 7. The departure coincided with the release of the half-year results, in which Evotec confirmed its already-reduced full-year 2026 guidance. Since her exit, the share price has fallen 13.0%. No direct causal link can be drawn, but the accumulation of negative developments has weighed on investor confidence broadly.
What November 5 Will Tell
Attention now shifts to November 5, 2026, when Evotec reports third-quarter results. With the annual forecast already cut, the central question is whether the company can land at the lower or upper end of its revenue and EBITDA ranges.
Until then, the stock remains in a fragile state. Neither the fresh research collaborations nor the cost-savings program has sparked a turnaround. Whether the Q3 report changes that narrative depends largely on whether the milestone payments deferred over the summer actually flow in next year as promised — or whether further delays lie ahead.
The picture for investors is genuinely mixed. On the scientific side, Evotec is delivering evidence of its platform strength: JST-018 has entered the clinic, and the Plectonic and Odyssey alliances add further proof points. The market, however, is currently assigning those advances secondary importance relative to the fundamental question of whether the reduced guidance confirmed during the summer will hold. As long as that uncertainty persists, the shares look likely to stay trapped in their downtrend — no matter how many new partnerships are announced.
Ad
Evotec Stock: New Analysis - 12 September
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
